ow grade ovarian cancer treatment
Phase 2
- Conditions
- Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2019/08/020566
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a. Age 18 â?? 75 years
b. Stage II â?? stage IV LGSC
c. Patients who have undergone either upfront cytoreductive surgery or who have received neoadjuvant chemotherapy and then underwent cytoreductive surgery.
d. ER and /or PR positive cases.
Exclusion Criteria
a. Patients who received chemotherapy post cytoreductive surgery.
b. Recurrent cases of low-grade serous cancer of ovary/peritoneum.
c. Cells showing morphological features of LGSC with moderate nuclear atypia and >= 70% cells showing diffuse strong P53 mutations or null type P53.
d. ER and PR negative LGSC
e. Exclude if fertility sparing conservative surgery is undertaken
f. Low grade serous ovarian/fallopian tube/ cancer during pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survivalTimepoint: 3 and 5 years
- Secondary Outcome Measures
Name Time Method Overall SurvivalTimepoint: 3 and 5 years;Quality of Life Assessment by using TMH Mini Quality of Life (Qol) questionnaireTimepoint: Prior to surgery, at 6 month follow-up, and yearly thereafter till initiation of second line treatment when needed.